IONS - Ionis Pharma gets positive views from analysts; slide extends to developers on HT

Ionis Pharmaceuticals ([[IONS]] -22.5%) has lost almost a fifth after announcing that the partner Roche Holding ([[RHHBY]] -3.3%) has discontinued the dosing in the Phase III GENERATION HD1 study for Tominersen in manifest Huntington's disease (“HD”).An investigational antisense therapy, Tominersen is designed to reduce the production of the huntingtin protein (“HTT”), including its mutated form, mHTT.Keeping the outperform rating, RBC Capital Markets has cut the price target of Ionis to $65.00 from $76.00 per share indicating ~16.8% upside to the previous close.Ionis’ efforts in HD ‘was never central to our thesis’ the analyst wrote expecting Wave Life Sciences ([[WVE]] -20.4%) and uniQure ([[QURE]] -9.0%) to suffer a more direct negative impact from the development.Meanwhile, with an outperform rating on Ionis, Oppenheimer views the current valuation as an attractive entry point citing the setback suffered by the company was in line with its outlook. The price target of $63.00 per share indicates a

For further details see:

Ionis Pharma gets positive views from analysts; slide extends to developers on HT